Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylprednisolone + efgartigimod
- Development stage
- Preclinical
- Lead developer
- argenx
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of methylprednisolone, a corticosteroid with anti-inflammatory and immunosuppressive properties, and efgartigimod, a neonatal Fc receptor (FcRn) blocker. This combination works by reducing pathogenic IgG antibodies through efgartigimod's blockade of FcRn-mediated antibody recycling, while methylprednisolone provides anti-inflammatory effects. The combination has shown efficacy in treating autoimmune conditions including neuromyelitis optica spectrum disorders (NMOSD), immune-mediated necrotizing myopathy (IMNM), and myasthenic crisis in generalized myasthenia gravis.
02
Targets
GR (Glucocorticoid receptor)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on methylprednisolone + efgartigimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylprednisolone + efgartigimod.